Biotricity (Biotricity) Total Liabilities : $32.21 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biotricity Total Liabilities?

Biotricity's Total Liabilities for the quarter that ended in Dec. 2023 was $32.21 Mil.

Biotricity's quarterly Total Liabilities increased from Jun. 2023 ($29.56 Mil) to Sep. 2023 ($32.30 Mil) but then declined from Sep. 2023 ($32.30 Mil) to Dec. 2023 ($32.21 Mil).

Biotricity's annual Total Liabilities increased from Mar. 2021 ($11.27 Mil) to Mar. 2022 ($18.82 Mil) and increased from Mar. 2022 ($18.82 Mil) to Mar. 2023 ($26.36 Mil).

Biotricity Total Liabilities Historical Data

The historical data trend for Biotricity's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotricity Total Liabilities Chart

Biotricity Annual Data

Trend

Aug14

Aug15

Dec16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Liabilities

Get a 7-Day Free Trial

2.27

5.01

11.27

18.82

26.36

Biotricity Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															22.13	26.36	29.56	32.30	32.21

Biotricity Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biotricity's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.161	+	(14.436	+	0.759
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	26.36

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	6.511	-	-19.845
	=	26.36

Biotricity's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18.619	+	(12.456	+	1.139
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	32.21

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	5.486	-	-26.727
	=	32.21

Biotricity Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biotricity's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotricity (Biotricity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biotricity Inc (NAS:BTCY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

QB00:Germany

Address

275 Shoreline Drive, Suite 150, Redwood City, CA, USA, 94065

Website

https://www.biotricity.com

Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed, which is a virtual clinic platform that enables clinicians to provide outstanding patient care remotely; Bioheart, which is a personal heart monitor; and Biocare health.

Executives

Chester P White	director	447 BATTERY STREET, SUITE 230, SAN FRANCISCO CA 94111
Ronald W. Mcclurg	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Stephen Salmon	director	1177 HAGEN ROAD, NAPA CA 94558
Patricia J Kennedy	director	275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Norman M. Betts	director	275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
Waqaas Al-siddiq	director, 10 percent owner, officer: CEO and Chairman of the Board	C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065
John Ayanoglou	officer: Chief Financial Officer	C/O 275 SHORELINE DRIVE, SUITE 150, REDWOOD CITY CA 94065